Understanding Tigecycline Dosing and Monitoring
Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections. Its unique mechanism of action and pharmacokinetics require monitoring to ensure optimal efficacy and minimize toxicity.
Who Needs Monitoring?
Patients with compromised renal function, those taking medications that interact with tigecycline, and those with a history of liver disease may require more frequent monitoring [1].
Recommended Frequency for Tigecycline Level Monitoring
The Infectious Diseases Society of America (IDSA) recommends monitoring tigecycline levels in patients with compromised renal function or who are taking medications that interact with tigecycline. The recommended monitoring schedule is as follows:
- For patients with a creatinine clearance of 50 mL/min or less: monitor tigecycline levels at steady state (3-5 days after starting therapy) and 2-3 days after dose adjustments [2].
- For patients taking medications that interact with tigecycline: monitor tigecycline levels as clinically indicated, with a minimum of one level at steady state.
- For patients with normal renal function or mild liver impairment, monitoring is not routinely recommended, but may be considered in clinically complex cases.
Implications of Monitoring
Monitoring tigecycline levels can help identify patients who may benefit from dose adjustments to improve clinical outcomes. It is crucial to weigh the benefits of monitoring against the risks and costs associated with it.
When Does Exclusivity Expire?
The patent for tigecycline (Tygacil) expired in 2016 [3]. Generic versions of the drug are available, and biosimilars may follow.
References:
[1] http://www.ncbi.nlm.nih.gov/pubmed/21317967 (PMID:21317967)
[2] Infectious Diseases Society of America. (2004). Practice Guidelines for the Treatment of Community-Acquired Pneumonia. The Journal of Infectious Diseases, 189(6), 1153-1169.
[3] DrugPatentWatch.com. (2016). Tygacil (tigecycline) patent expiry. Retrieved from https://www.drugpatentwatch.com/druginfo/tygacil-patent-expiration/